BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30337268)

  • 1. Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis.
    Rice SR; Molitoris JK; Vyfhuis MAL; Edelman MJ; Burrows WM; Feliciano J; Nichols EM; Suntharalingam M; Donahue J; Carr SR; Friedberg J; Badiyan S; Simone CB; Feigenberg SJ; Mohindra P
    Clin Lung Cancer; 2019 Jan; 20(1):e107-e114. PubMed ID: 30337268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.
    Matys T; Drury R; David S; Rassl DM; Qian W; Rintoul RC; Screaton NJ
    Lung Cancer; 2018 Aug; 122():195-199. PubMed ID: 30032831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Imaging for Staging of Patients With Clinical Stage IA Non-small Cell Lung Cancer in the National Lung Screening Trial: Adherence With Recommendations From the Choosing Wisely Campaign.
    Balekian AA; Fisher JM; Gould MK
    Chest; 2016 Apr; 149(4):943-50. PubMed ID: 26356134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?
    Shi AA; Digumarthy SR; Temel JS; Halpern EF; Kuester LB; Aquino SL
    J Thorac Oncol; 2006 Mar; 1(3):205-10. PubMed ID: 17409858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history, clinical course and predictors of interval time from initial diagnosis to development of subsequent NSCLC brain metastases.
    Smith DR; Bian Y; Wu CC; Saraf A; Tai CH; Nanda T; Yaeh A; Lapa ME; Andrews JIS; Cheng SK; McKhann GM; Sisti MB; Bruce JN; Wang TJC
    J Neurooncol; 2019 May; 143(1):145-155. PubMed ID: 30874953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
    AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
    [No Abstract]   [Full Text] [Related]  

  • 7. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk factor analysis of mediastinal lymph node metastasis in non-small cell lung cancer patients and the strategy of mediastinoscopy prior to surgery].
    Wang X; Zheng L; Zhang SY; Xie ZM; Yu H; Su XD; Wang JY; Huang ZF; Yang MT; Rong TH
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):456-9. PubMed ID: 19950559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.
    Li X; Zhang H; Xing L; Xu X; Xie P; Ma H; Zhang L; Chen M; Sun X; Xu W; Chen L; Yu J
    Clin Lung Cancer; 2013 Sep; 14(5):568-73. PubMed ID: 23835164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe.
    Sakao Y; Okumura S; Mingyon M; Uehara H; Ishikawa Y; Nakagawa K
    J Thorac Oncol; 2011 Mar; 6(3):494-9. PubMed ID: 21266920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.
    Mujoomdar A; Austin JH; Malhotra R; Powell CA; Pearson GD; Shiau MC; Raftopoulos H
    Radiology; 2007 Mar; 242(3):882-8. PubMed ID: 17229875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients.
    Koike T; Koike T; Yamato Y; Yoshiya K; Toyabe S
    J Thorac Oncol; 2012 Aug; 7(8):1246-51. PubMed ID: 22659962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for node metastasis in patients with clinical stage I non-small cell lung cancer.
    Cho S; Song IH; Yang HC; Kim K; Jheon S
    Ann Thorac Surg; 2013 Jul; 96(1):239-45. PubMed ID: 23673071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and lymph node metastasis pathway of non-small-cell lung cancer located in the left lingular division.
    Shien K; Toyooka S; Soh J; Okami J; Higashiyama M; Kadota Y; Maeda H; Hayama M; Chida M; Funaki S; Okumura M; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):791-6. PubMed ID: 25805399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for hilar/intrapulmonary lymph node metastasis in discrete type of clinical N1 non-small cell lung cancer.
    Fukui T; Kato K; Okasaka T; Kawaguchi K; Fukumoto K; Nakamura S; Hakiri S; Ozeki N; Yokoi K
    Gen Thorac Cardiovasc Surg; 2017 Nov; 65(11):640-645. PubMed ID: 28866794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinicopathological features associated with skip N2 metastases in patients with clinical stage IA non-small-cell lung cancer.
    Gorai A; Sakao Y; Kuroda H; Uehara H; Mun M; Ishikawa Y; Nakagawa K; Masuda M; Okumura S
    Eur J Cardiothorac Surg; 2015 Apr; 47(4):653-8. PubMed ID: 24957260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.